Zentalis Pharmaceuticals Inc (ZNTL) - News Archive

: Zentalis Pharmaceuticals has showcased significant advancements in the development of their novel therapeutic, azenosertib. Recent data presentations at major conferences, including the AACR-NCI-EORTC International Co...

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a notable player in the biopharmaceutical sector, has recently announced its participation in a series of upcoming investor conferences. This initiative aligns with the com...

Zentalis Pharmaceuticals Continues Strategic Talent Acquisition with Substantial Stock Option Awards San Diego, Feb. 3, 2025 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a leading clinical-stage biopharmaceutical inno...

Zentalis Pharmaceuticals Strategic Stock Option Grants: Implications for Shareholders and Future OutlookSAN DIEGO In a bid to attract top talent in the competitive biotech space, Zentalis Pharmaceuticals, Inc. (Nasdaq:...

In a whirlwind of activity, Zentalis Pharmaceuticals finds itself at a pivotal juncture, marked by significant executive leadership changes, alarming financial metrics, and an aggressive strategy to attract top talent....

Zentalis Pharmaceuticals Strengthens Talent Acquisition with Substantial Inducement GrantsSAN DIEGO, Nov. 1, 2024 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on deve...

In a significant development for the biopharmaceutical industry, Zentalis Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on their investigational canc...

: Zentalis Pharmaceuticals has made significant advancements in cancer treatment methodology through the preclinical evaluation of Azenosertib, a potent drug candidate exhibiting synergistic effects when paired with top...

- DateZentalis Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics for cancer treatment, announced today that it has granted non-qualified stock opt...

Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company known for its groundbreaking research in developing small molecule therapeutics to target cancer pathways, recently announced the granting of non-qual...

Zentalis Pharmaceuticals Grants Inducement Stock Options to New EmployeesZentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapeutics for cancer treat...

Despite being a clinical-stage biopharmaceutical company with promising potential, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) is currently facing challenges that have impacted its stock performance. Several factors, in...

Update on the Clinical Development Program of Azenosertib by Zentalis Pharmaceuticals The clinical development of Azenosertib, a novel therapeutic agent developed by Zentalis Pharmaceuticals, has encountered significant...

Zentalis Pharmaceuticals Grants Stock Options to New Hires as Incentive for Joining CompanyIn a move to attract top talent and reward new employees, Zentalis Pharmaceuticals, Inc. announced today that it has granted non...

New York and San Diego, May 29, 2024 - Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapeutics to combat cancer, is excited to an...

: Zentalis Pharmaceuticals has announced promising initial findings from its Phase 1 clinical trial exploring the efficacy and safety of azenosertib in combination with gemcitabine for the treatment of relapsed or refra...

In a recent press release, Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapeutics, announced the granting of non-qualified stock options to three newly...

Facts:- Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company, announced on April 1, 2024, that they have granted non-qualified stock options to four newly hired employees.- The stock options allow the pu...

Zentalis Pharmaceuticals Grants Inducement Stock Options to New Hires, Adding to Total Outstanding SharesIn recent months, Zentalis Pharmaceuticals Inc. has been actively engaging in inducement grants under Nasdaq Listi...

In a strategic move aimed at bolstering its clinical development pipeline, Zentalis Pharmaceuticals, a leading clinical-stage biopharmaceutical company, announced the granting of non-qualified stock options and restrict...